Research Working Group - Updates from 2017

August 2017: Summer time and self-care
By Iveta Nohavova

When I was contemplating what topic I would focus on this month, I kept thinking about summer days calling us outside to relax, move, do fun activities, travel, or simply smell, listen and observe nature around us. This is also the time of summer vacations during which we aim to step away from our daily routines and perhaps even forget for a moment our duties or worries.

Iveta Nohavova
Iveta Nohavova

Have you already thanked yourself today for being the person you are?

Well, why not use this month to reflect on how important it is for we nurses to take good care of our bodies and minds because, undoubtedly, our profession demands a lot of empathy and care for others. And, over time, this can be exhausting, especially if we do not take care to replenish both our inner and our physical strength.

Have you taken 15 minutes today, just for you?

I want to invite you to:

  • sing for joy
  • dance with your eyes closed
  • draw a picture
  • take a walk in the woods
  • take a nap
  • enjoy a cup of tea with your friend
  • meditate about things you are thankful for
  • write an entry in your journal
  • compose a poem/
  • …etc.

In other words, simply do whatever makes you happy! And, if possible, do this every day.

Happy, healthy and content nurses provide the best nursing care and create a healthy work environment. Self-care is an essential instrument to prevent the burnout, moral distress and compassion fatigue of which we are at daily risk in our profession. So, do not forget to take care of yourselves. Summer is the ideal time to restore and replenish our reserves.

I would like to close with the following quote from Ovid:

“Take rest. The field that has rested gives a beautiful crop.”

July 2017: EONS research support helps cancer nurse gain PhD

EONS research support has helped Dr Ylva Hellstadius, an EONS nurse and PhD student at the Karolinska Institutet in Stockholm, Sweden, on her way to being an accomplished researcher and making a real difference to patient care.

EONS Research Working Group Co-chair Mary Wells, played a key part in this major achievement as one of her PhD examiners. Paying tribute to Ylva’s work, she commented: “Finishing a PhD is a major achievement in any nurse researcher’s life and it is quite right that it should be marked in a formal way. Having been a PhD examiner for a number of theses in the UK, I was excited to be asked, for the first time, to be an ‘opponent’ for a PhD student at the Karolinska Institutet in Stockholm, Sweden. I was particularly looking forward to it as the student was Ylva, who took part in our second EONS Research Workshop in Stockholm in 2012, when she was just embarking on her doctoral studies.

Mary Wells
Mary Wells

“Ylva was also a deserving winner of an EONS Research Travel Grant a few years later, and this grant enabled her to spend some time at St Thomas’ Hospital in London, where she conducted two of her research studies. Ylva’s thesis explored psychological distress in patients with oesophageal cancer. Her work included three published quantitative studies illustrating significant levels of anxiety and depression in patients before surgery, at sixth months and also at five years after surgery. She also conducted an in-depth qualitative study (to be published) which revealed important insights into the often hidden distress reactions experienced by patients who have had treatment for this devastating disease.”

Ylva Hellstadius receives her 2013 Research Travel Grant from EONS Board member and Advocacy Working Group chair Patrick Crombez.
Ylva Hellstadius receives her 2013 Research Travel Grant from EONS Board member and Advocacy Working Group chair Patrick Crombez.

Explaining her role, Mary continued: “As the opponent, I was required to ask Ylva a range of searching questions about her work in front of an audience of family, friends, supervisors and colleagues, and in the presence of an examining committee. This is very different from the PhD viva voce examination which takes place in the UK, as this involves only the examiners and student discussing the work in a private room.

“There is something much more ceremonial about the system in Sweden and it was a really interesting experience for me, as well as being quite a demanding one! But the best thing about it was seeing Dr Ylva Hellstadius, an EONS nurse, achieve her PhD. It’s fantastic to see that EONS research support has helped her on her way to being an accomplished researcher whose work will make a real difference to patient care.”

Find out more about how EONS grants and awards could help you build your research skills.

March 2017: Unleashing the power of nature in advanced symptom management: the case of thyme honey in xerostomia

By Andreas Charalambous, Assistant Professor of Oncology Nursing and Palliative Care, Nursing Faculty, Cyprus University of Technology and Docent at University of Turku, Finland.

Cancer treatments including immunotherapy have all been associated with numerous adverse effects of varying levels of severity, including oral toxicities and cutaneous toxicities, to name a few. One of the most prominent and persistent side effects for patients with malignancy undergoing chemotherapy and/or radiotherapy is xerostomia. These adverse effects, when severe, can cause dose limitation, interruption of treatment, difficulties in performing the activities of daily living and subsequently increasing the negative impact on the patient’s overall Health-Related Quality of Life (Charalambous, 2014).

Xerostomia is the abnormal dryness in the mouth characterized by a marked decrease and/or thickening of saliva, resulting from the reduction or absence of sufficient quantity of salivary production. For example, radiation therapy as monotherapy (worse effects observed when radiotherapy is combined with chemotherapy such as increased duration of xerostomia) can reduce the salivary flow rate by up to 80% by the 7th week (Li et al., 2007). As a result the patient has to deal with difficulties in eating and swallowing that in turn lead to limited intake of food and liquids, causing severe malnutrition and secondary infections.

The pharmacological options available for the comprehensive management of xerostomia remain ineffective and with many presenting with low adherence among patients (i.e. pilocarpine, artificial saliva). The value of complementary and alternative (CAM) interventions such as thyme honey in the management of xerostomia has not been fully captured in the literature. The fact that an increased number of people will have to live with this side-effect during the treatment and soon after its completion, has created a more positive trend towards the value and effectiveness of CAM interventions both among patients and healthcare professionals.

Honey is one of products in nature’s arsenal that have been studied to an extent for the management of H&N cancer treatment adverse-effects, but not for xerostomia. Honey has many properties that can prospectively be of high value in managing xerostomia. For example, honey presence in the oral cavity can have a sialagogue effect by stimulating the salivary glands (i.e. minor salivary glands) to produce more saliva (Ganjre et al., 2015). Honey also has excellent antibacterial action due to the presence of phytochemicals (Anderson, 2006) and its acidic environment with a pH ranging from 3.2 to 4.5 (Bardy et al., 2008:1). The antibacterial properties of honey can be further fortified by those of thyme, which also has strong anti-inflammatory and pain-relief actions when used locally.

We have recently published the first study that was designed to explore the effectiveness of thyme honey in xerostomia (Charalambous et al 2017). This was a parallel randomised controlled trial with two equal arms, the experimental arm (thyme honey) and the control arm (saline). Seventy-two head and neck cancer patients receiving radiotherapy or/and chemotherapy or/and surgery were recruited for this trial. Patients in both arms followed the same administration protocol with thyme honey and saline respectively. Identical assessments at baseline, 1 month and 6 months following completion of the intervention were performed in both arms including the National Cancer Institute (NCI) xerostomia scale and the Xerostomia Questionnaire (XQ) additionally to weekly oral clinical assessments. The ClinicalTrials.gov Identifier for this study is NCT01465308. The study’s results demonstrated the safety and efficacy of Thyme honey in head and neck cancer patients for the management of treatment induced xerostomia. Thyme honey was found effective in reducing or stabilizing the severity of xerostomia grade and improving overall health related quality of life. Its positive effects on xerostomia grade increased over time. However, this being the first study exploring the safety and effectiveness of thyme honey in xerostomia, there is a need for further larger, multi-site and high quality studies to validate these findings.

References

Anderson I.Honey dressings in wound care. Nurs. Times, 102 (2006), pp. 40-42

Bardy, J.N. Slevin, L.K. Mais, et al. A systematic review of honey uses and its potential value within oncology care J. Clin. Nurs., 17 (2008), pp. 2604-2623

Charalambous, A. Charalambous M. Hermeneutic phenomenological interpretations of patients with head and neck neoplasm experiences living with radiation-induced xerostomia: the price to pay? Eur. J. Oncol. Nurs., 18 (2014), pp. 512-520.

Charalambous A, Lambrinou A, Katodritis N, Vomvas D, Raftopoulos V, Georgiou M, Paikousis L, Charalambous M. The effectiveness of thyme honey for the management of treatment-induced xerostomia in head and neck cancer patients: A feasibility randomized control trial, European Journal of Oncology Nursing, 27(2017), pp 1-8

Ganjre, A, K. Rahul, V. Pawar, N. Bagul, et al. Anti-carcinogenic and anti-bacterial properties of selected spices Implic. Oral Health Clin Nutr Res., 4 (2015), pp. 209-215.

Y. Li, J.M. Taylor, R.K. Ten, Haken. The impact of dose on parotid salivary recovery in head and neck cancer patients treated with radiation therapy. Int. J. Radiat. Oncol. Biol. Phys., 67 (3, 1) (2007), pp. 660-669.

February 2017: Personalised medicine

Personalised medicine aims to tailor treatment to the patient’s individual biology. Recent advances in genetic science are revolutionising cancer treatment. For the February Research News Update, Professor Theresa Wiseman shares an article from the journal Oncology.
+  Read the article


//